Meixiao Long

3.4k total citations · 1 hit paper
49 papers, 1.8k citations indexed

About

Meixiao Long is a scholar working on Immunology, Genetics and Oncology. According to data from OpenAlex, Meixiao Long has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 15 papers in Genetics and 13 papers in Oncology. Recurrent topics in Meixiao Long's work include Chronic Lymphocytic Leukemia Research (14 papers), Immune Cell Function and Interaction (12 papers) and T-cell and B-cell Immunology (11 papers). Meixiao Long is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Immune Cell Function and Interaction (12 papers) and T-cell and B-cell Immunology (11 papers). Meixiao Long collaborates with scholars based in United States, South Korea and Japan. Meixiao Long's co-authors include Sankar Ghosh, Matthew S. Hayden, Sung‐Gyoo Park, Ian Strickland, Adam C. Adler, Marianne A. Mihalyo, John C. Byrd, Amy J. Johnson, Liming Hao and Natarajan Muthusamy and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Meixiao Long

46 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib treatment improves T cell number and function in CLL patients

2017 288 citations Meixiao Long, Kami J. Maddocks et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meixiao Long United States	19	1.1k	648	448	283	265	49	1.8k
Danyi Wen China	14	570 0.5×	511 0.8×	446 1.0×	405 1.4×	157 0.6×	22	1.5k
Eva Sahakian United States	18	727 0.7×	838 1.3×	833 1.9×	121 0.4×	167 0.6×	66	1.7k
Natasha M. Savage United States	18	585 0.5×	557 0.9×	488 1.1×	161 0.6×	116 0.4×	79	1.4k
Lixin Rui United States	19	986 0.9×	374 0.6×	724 1.6×	221 0.8×	169 0.6×	37	1.9k
Maciej Kmieciak United States	24	876 0.8×	971 1.5×	849 1.9×	225 0.8×	88 0.3×	66	2.0k
Erik A. Nelson United States	23	869 0.8×	887 1.4×	907 2.0×	212 0.7×	299 1.1×	38	2.3k
Yanyan Han China	10	568 0.5×	870 1.3×	691 1.5×	317 1.1×	162 0.6×	21	1.9k
Jingda Xu China	17	390 0.4×	643 1.0×	771 1.7×	242 0.9×	100 0.4×	24	1.4k
Fanny Baran‐Marszak France	20	440 0.4×	467 0.7×	428 1.0×	111 0.4×	435 1.6×	45	1.2k
Shweta Joshi United States	23	403 0.4×	382 0.6×	655 1.5×	239 0.8×	137 0.5×	48	1.5k

Countries citing papers authored by Meixiao Long

Since Specialization

Citations

This map shows the geographic impact of Meixiao Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meixiao Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meixiao Long more than expected).

Fields of papers citing papers by Meixiao Long

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meixiao Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meixiao Long. The network helps show where Meixiao Long may publish in the future.

Co-authorship network of co-authors of Meixiao Long

This figure shows the co-authorship network connecting the top 25 collaborators of Meixiao Long. A scholar is included among the top collaborators of Meixiao Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meixiao Long. Meixiao Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mao, Charlene, et al.. (2024). Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia. Nature Communications. 15(1). 5180–5180. 5 indexed citations

Su, Po‐Lan, Naoki Furuya, Meixiao Long, et al.. (2024). DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Molecular Cancer. 23(1). 97–97. 25 indexed citations

Zhao, Bao, Anjun Ma, Jianwen Chen, et al.. (2022). SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. Nature Immunology. 23(11). 1588–1599. 18 indexed citations

Jiang, Junjie, Jiao Yuan, Zhongyi Hu, et al.. (2022). Systematic illumination of druggable genes in cancer genomes. Cell Reports. 38(8). 110400–110400. 24 indexed citations

Hu, Zhongyi, Jiao Yuan, Meixiao Long, et al.. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nature Cancer. 2(12). 1406–1422. 61 indexed citations

Harrington, Bonnie K., Esther F. Wheeler, Youssef Youssef, et al.. (2019). Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia & lymphoma. 60(10). 2498–2507. 23 indexed citations

Westervelt, Peter, Jörge E. Cortes, Jessica K. Altman, et al.. (2019). Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 834–834. 49 indexed citations

Hu, Zhongyi, Junjie Jiang, Jiao Yuan, et al.. (2019). Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nature Communications. 10(1). 733–733. 40 indexed citations

Long, Meixiao, Carolyn Cheney, Eileen Hu, et al.. (2019). Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity. Blood. 134(Supplement_1). 1049–1049. 3 indexed citations

10.

Park, Sung‐Gyoo, Meixiao Long, Jung‐Ah Kang, et al.. (2013). The Kinase PDK1 Is Essential for B-Cell Receptor Mediated Survival Signaling. PLoS ONE. 8(2). e55378–e55378. 19 indexed citations

11.

Park, Sung‐Gyoo, Ramkumar Mathur, Meixiao Long, et al.. (2010). T Regulatory Cells Maintain Intestinal Homeostasis by Suppressing γδ T Cells. Immunity. 33(5). 791–803. 143 indexed citations

12.

Bandyopadhyay, Suman, Meixiao Long, Adam T. Hagymasi, et al.. (2008). Self-Antigen Prevents CD8 T Cell Effector Differentiation by CD134 and CD137 Dual Costimulation. The Journal of Immunology. 181(11). 7728–7737. 15 indexed citations

13.

Jimi, Eijiro, Ian Strickland, Reinhard Voll, Meixiao Long, & Sankar Ghosh. (2008). Differential Role of the Transcription Factor NF-κB in Selection and Survival of CD4+ and CD8+ Thymocytes. Immunity. 29(4). 523–537. 45 indexed citations

14.

Long, Meixiao, Shuang Wu, Adam T. Hagymasi, et al.. (2007). Histone Acetylation at the Ifng Promoter in Tolerized CD4 Cells Is Associated with Increased IFN-γ Expression during Subsequent Immunization to the Same Antigen. The Journal of Immunology. 179(9). 5669–5677. 7 indexed citations

15.

Kappos, Ludwig, D. H. Miller, David MacManus, et al.. (2006). Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. UCL Discovery (University College London). 13 indexed citations

16.

Long, Meixiao & Adam C. Adler. (2006). Cutting Edge: Paracrine, but Not Autocrine, IL-2 Signaling Is Sustained during Early Antiviral CD4 T Cell Response. The Journal of Immunology. 177(7). 4257–4261. 45 indexed citations

17.

Long, Meixiao, Adam T. Hagymasi, Marianne A. Mihalyo, et al.. (2006). T-bet Down-Modulation in Tolerized Th1 Effector CD4 Cells Confers a TCR-Distal Signaling Defect That Selectively Impairs IFN-γ Expression. The Journal of Immunology. 176(2). 1036–1045. 16 indexed citations

18.

Drake, Charles G., Marianne A. Mihalyo, Ching-Tai Huang, et al.. (2005). Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 7(3). 239–249. 226 indexed citations

19.

Mihalyo, Marianne A., Jeremy P. McAleer, Elizabeth C. Nowak, et al.. (2004). In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy. The Journal of Immunology. 172(9). 5338–5345. 30 indexed citations

20.

Long, Meixiao, et al.. (2003). Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-α and IFN-γ expression potentials. Cellular Immunology. 224(2). 114–121. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact